🇺🇸 anti thymoglobulin in United States
20 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 20
Most-reported reactions
- Atrial Thrombosis — 2 reports (10%)
- Candida Sepsis — 2 reports (10%)
- Coccidioidomycosis — 2 reports (10%)
- Cryptococcosis — 2 reports (10%)
- Enterococcal Sepsis — 2 reports (10%)
- Epstein-Barr Virus Infection — 2 reports (10%)
- Leukopenia — 2 reports (10%)
- Pancytopenia — 2 reports (10%)
- Phaeohyphomycosis — 2 reports (10%)
- Transplant Rejection — 2 reports (10%)
Other Immunology approved in United States
Frequently asked questions
Is anti thymoglobulin approved in United States?
anti thymoglobulin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for anti thymoglobulin in United States?
Peking University People's Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.